Share this video with your pharmacist friends:
This publication is sponsored by :
BeiGene Canada
A question ?
Contact usUnderstanding the role of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of hematological cancers
CCCEP: #1296-2024-3824-I-P
Author(s):
Annick Dufour, B.Pharm, M.Sc.
Reviewer(s):
Justine Couturier, B.Pharm, M.Sc., Pharmacist, Centre intégré de cancérologie de Laval (CICL) and GMF Medicentre Chomedey
Emie Desruisseaux, Pharm.D., M.Sc.
Speaker(s):
Tina Crosbie, BSc. (Pharm), ACPR, RPh, Clinical Pharmacist, Hematology and Past President, Canadian Association of Pharmacy in Oncology (CAPhO)
To view this activity, add it to your personal space.
Add the activity
to your account
and watch it
Pass the quiz
to obtain
your CEUs
Complete the
activity evaluation
Obtain your statement
of attendance
To discover without delay!
Other activities that might interest you!
Webinar
Basal Insulin Update: Optimizing Therapeutic Adjustment (Module 2)
30 minutes
Published September 11, 2024
Webinar
A practical guide to GLP-1 agonists in the management of type 2 diabetes : Patient management (module 2)
30 minutes
Published May 21, 2024
Webinar
Basal Insulin Update: The Role of Basal Insulin in Type 2 Diabetes Management (Module 1)
30 minutes
Published September 11, 2024
